Sep 05, 2019
CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City
Sep 03, 2019
CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference
Aug 09, 2019
CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results
Jun 17, 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Jun 03, 2019
CASI Pharmaceuticals To Present At The 2019 BIO International Convention
May 15, 2019
CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
Apr 02, 2019
CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
Mar 13, 2019
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
Mar 07, 2019
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
Feb 19, 2019
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
Feb 06, 2019
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
Dec 03, 2018
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
Nov 16, 2018
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
Nov 14, 2018
CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
Oct 23, 2018
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
Oct 02, 2018
CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
Sep 14, 2018
CASI Pharmaceuticals Announces $48.5 Million Private Placement
Aug 14, 2018
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
Jul 03, 2018
CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes
Jun 21, 2018
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol